These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9288701)

  • 1. Efficacy and tolerability of Estraderm MX, a new estradiol matrix patch.
    Bacchi-Modena A; Bolis P; Campagnoli C; De Cicco F; Meschia M; Pansini F; Pisati R; Hüls G
    Maturitas; 1997 Jul; 27(3):285-92. PubMed ID: 9288701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of a new estradiol delivering matrix patch (Estraderm MX) in postmenopausal women.
    de Vrijer B; Snijders MP; Troostwijk AL; Thé S; Iding RJ; Friese S; Smit DA; Schierbeek JM; Brandts H; van Kempen PJ; van Buuren I; Monza G
    Maturitas; 2000 Jan; 34(1):47-55. PubMed ID: 10687882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 17Beta-estradiol delivered by three different matrix patches 50 microg/day: a three way cross-over study in 21 postmenopausal women.
    Rohr UD; Nauert C; Stehle B
    Maturitas; 1999 Sep; 33(1):45-58. PubMed ID: 10585173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study.
    Pornel B; Genazzani AR; Costes D; Dain MP; Lelann L; Vandepol C
    Maturitas; 1995 Nov; 22(3):207-18. PubMed ID: 8746878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy on climacteric symptoms of a new estradiol transdermal patch with active matrix in comparison with a reference reservoir patch. Two long-term randomized multicenter parallel-group studies.
    Rovati LC; Schmid K; Giacovelli G; Bonn M; Setnikar I; Wolff F; Genazzani AR
    Arzneimittelforschung; 1999 Nov; 49(11):933-43. PubMed ID: 10604047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with a seven-day estradiol transdermal system for estrogen replacement therapy.
    Gordon SF
    Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 2):998-1004. PubMed ID: 7573298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms.
    Speroff L; Whitcomb RW; Kempfert NJ; Boyd RA; Paulissen JB; Rowan JP
    Obstet Gynecol; 1996 Oct; 88(4 Pt 1):587-92. PubMed ID: 8841224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum concentrations of 17beta-estradiol and estrone after multiple-dose administration of percutaneous estradiol gel in symptomatic menopausal women.
    Brennan JJ; Lu Z; Whitman M; Stafiniak P; van der Hoop RG
    Ther Drug Monit; 2001 Apr; 23(2):134-8. PubMed ID: 11294513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of a new 7-day transdermal estradiol patch versus placebo in hysterectomized women with postmenopausal complaints.
    von Holst T; Salbach B
    Maturitas; 2000 Feb; 34(2):143-53. PubMed ID: 10714909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). II. Local skin tolerability.
    Rozenbaum H; Birkhäuser M; De Nooyer C; Lambotte R; Pornel B; Schneider H; Studd J; Thebault J
    Maturitas; 1996 Nov; 25(3):175-85. PubMed ID: 8981334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of estradiol and of estrone during application of a new 7-day estradiol transdermal patch with active matrix.
    Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
    Arzneimittelforschung; 1998 Mar; 48(3):275-85. PubMed ID: 9553686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). I. Tolerability, adhesion and efficacy.
    Rozenbaum H; Birkhäuser M; De Nooyer C; Lambotte R; Pornel B; Schneider H; Studd J
    Maturitas; 1996 Nov; 25(3):161-73. PubMed ID: 8981333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-response efficacy of a new estradiol transdermal matrix patch for 7-day application: a randomized, double-blind, placebo-controlled study. Italian Menopause Research Group.
    Rovati LC; Setnikar I; Genazzani AR
    Gynecol Endocrinol; 2000 Aug; 14(4):282-91. PubMed ID: 11075300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy on climacteric symptoms and safety of low dose estradiol transdermal matrix patches. A randomized, double-blind placebo-controlled study.
    De Aloysio D; Rovati LC; Giacovelli G; Setnikar I; Bottiglioni F
    Arzneimittelforschung; 2000 Mar; 50(3):293-300. PubMed ID: 10758784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized comparison of intranasal and transdermal estradiol.
    Lopes P; Merkus HM; Nauman J; Bruschi F; Foidart JM; Calaf J
    Obstet Gynecol; 2000 Dec; 96(6):906-12. PubMed ID: 11084176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
    Bachmann GA; Schaefers M; Uddin A; Utian WH
    Obstet Gynecol; 2007 Oct; 110(4):771-9. PubMed ID: 17906008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerance of Menorest compared to Premarin in the treatment of postmenopausal women. A randomised, multicentre, double-blind, double-dummy study.
    Studd JW; McCarthy K; Zamblera D; Burger HG; Silberberg S; Wren B; Dain MP; Le Lann L; Vandepol C
    Maturitas; 1995 Sep; 22(2):105-14. PubMed ID: 8538478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a new transdermal delivery system for estrogen replacement therapy in postmenopausal women.
    Figueroa-Casas PR; Alfonsin A; Arrighi A; Bluvstein G; Del Castillo R; Goldsman T; Inglesi J; Itala J; Novelli J; Monti C
    Maturitas; 1994 Dec; 20(2-3):139-44. PubMed ID: 7715465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study.
    Asthana S; Craft S; Baker LD; Raskind MA; Birnbaum RS; Lofgreen CP; Veith RC; Plymate SR
    Psychoneuroendocrinology; 1999 Aug; 24(6):657-77. PubMed ID: 10399774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Markedly elevated levels of estrone sulfate after long-term oral, but not transdermal, administration of estradiol in postmenopausal women.
    Slater CC; Hodis HN; Mack WJ; Shoupe D; Paulson RJ; Stanczyk FZ
    Menopause; 2001; 8(3):200-3. PubMed ID: 11355042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.